Source: Monash University
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Immuron (IMC) has entered a research agreement with Monash University to analyse the IMM-124E drug and its relevance to SARS-CoV-2
  • IMM-124E is the active pharmaceutical ingredient used to make Immuron’s over-the-counter gastrointestinal and digestive health products, Travelan and Protectyn
  • These products work by relieving traveller’s diarrhoea and supporting digestive health, however, the IMM-124E drug has shown antiviral activity against SARS-CoV-2 — which is the virus that causes COVID-19
  • While COVID-19 patients are known to have respiratory problems, symptoms like diarrhoea, vomiting and cramping have also been observed
  • The research team will be led by Monash’s Dr Melanie Hutton and Professor Dena Lyras
  • Professor Lyras will obtain a SARS-CoV-2 Spike protein and an antibody-positive human serum to research the inhibitory efficacy of Immuron’s drug
  • Immuron is up 6.25 per cent and shares are trading at 25.5 cents

Immuron (IMC) has entered a research agreement with Monash University to evaluate the efficacy of IMM-124E and advance SARS-CoV-2 findings.

IMM-124E is the active pharmaceutical ingredient used to make Immuron’s over-the-counter gastrointestinal and digestive health immune supplements, Travelan and Protectyn.

Earlier this year, the biopharmaceutical company reported the IMM-124E drug neutralises activity against COVID-19. The drug underwent testing which showed antiviral activity against SARS-CoV-2 — which is the virus that causes COVID-19.

While COVID-19 patients are known to have respiratory problems, gastrointestinal symptoms such as diarrhoea, vomiting and cramping have been observed in more and more patients who don’t show respiratory symptoms.

Immuron has since been engaging with research collaborators to further develop the antiviral activity of IMM-124E and further characterise the neutralisation of SARS-CoV-2.

The research team will be led by Dr Melanie Hutton and Professor Dena Lyras, who is the Deputy Director of the Biomedicine Discovery Institute and the Deputy Head of the Department of Microbiology.

Professor Lyras will utilise two new recombinant reagents, being the SARS-CoV-2 Spike protein and an antibody-positive human serum sample taken from Melbourne’s Peter Doherty Institute for Infection and Immunity.

“We have been very fortunate to obtain access to the SARS-CoV-2 recombinant proteins developed at the Peter Doherty Institute for Infection and Immunity,” Professor Lyras said.

“These reagents will be used to initiate the research work and to develop a suitable assay for evaluating the inhibitory efficacy of IMM-124E,” she added.

Immuron is up 6.25 per cent and shares are trading at 25.5 cents at 12:15 pm AEDT.

IMC by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…